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Abstract
Rhinovirus (RV) infection is a major cause of asthma exacerbations which may be due to a deficient innate immune response
in the bronchial epithelium. We hypothesized that the pleiotropic cytokine, TGF-b, influences interferon (IFN) production by
primary bronchial epithelial cells (PBECs) following RV infection. Exogenous TGF-b2 increased RV replication and decreased
IFN protein secretion in response to RV or double-stranded RNA (dsRNA). Conversely, neutralizing TGF-b antibodies
decreased RV replication and increased IFN expression in response to RV or dsRNA. Endogenous TGF-b2 levels were higher
in conditioned media of PBECs from asthmatic donors and the suppressive effect of anti-TGF-b on RV replication was
significantly greater in these cells. Basal SMAD-2 activation was reduced when asthmatic PBECs were treated with anti-TGF-
b and this was accompanied by suppression of SOCS-1 and SOCS-3 expression. Our results suggest that endogenous TGF-
b contributes to a suppressed IFN response to RV infection possibly via SOCS-1 and SOCS-3.
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Introduction
Asthma is a chronic inflammatory disease, characterized by
wheezing and bronchial hyperresponsiveness [1;2]. Human
rhinovirus (RV) infection is a major cause of asthma exacerbations
both in children and in adults worldwide [3]. Infection of epithelial
cells with RV leads to the initiation of the innate immune response
involving type I and type III interferons (IFNs), and expression of
proinflammatory cytokines. Binding of IFNs to their receptors can
occur in an autocrine or paracrine fashion, activating the JAK-
STAT pathway to induce expression of more IFNs, stimulate the
cellular antiviral machinery, and cause apoptosis of infected cells
to limit spread of the viral infection. Previous studies have shown
that primary bronchial epithelial cells (PBECs) from asthmatic
patients produce significantly lower levels of IFN-b and IFN-l in
response to RV infection when compared to PBECs obtained from
non-asthmatic volunteers [4;5]. This effect was associated with
increased viral replication in and enhanced cytopathic cell death of
the asthmatic cells [4].
The transforming growth factor beta (TGF-b) cytokine family
has pleiotropic effects [6] including potent anti-inflammatory and
profibrogenic activities which have been linked to airway
remodelling in asthma [7;8]. TGF-b1 and TGF-b2 are produced
by a variety of cells in asthmatic airways, including eosinophils [9]
and bronchial epithelial cells [10], respectively. It has been
suggested that, in asthma, persistent epithelial damage leads to
a chronic wound scenario associated with sustained release of
TGF-b2 and activation of subepithelial fibroblasts leading to drive
airway remodelling [10;11]. In studies of viral infection, exogenous
TGF-b has been reported to markedly increase replication of
respiratory syncytial virus (RSV) in PBECs from healthy donors
via a mechanism involving decreased cellular metabolism which
reduced the competition for substrates during viral replication
[12]. RSV is an enveloped virus which causes lower respiratory
tract infections in infants and, like RV, has been implicated in
asthma exacerbations [13]. More recently, treatment of bronchial
fibroblasts with exogenous TGF-b1 to induce myofibroblast
differentiation was also found to promote RV replication and this
was linked to decreased IFN gene expression [14]. Since epithelial
expression of TGF-b isoforms is increased in asthma [8;15], we
hypothesized that endogenous production of TGF-b by asthmatic
PBECs contributes to their lower innate immune response to RV
infection. Therefore, we have investigated whether neutralization
of endogenous TGF-b in cultures from asthmatic donors reduced
viral replication. Conversely, we also investigated whether
treatment of PBECs from non-asthmatic volunteers with exoge-
nous TGF-b2 resulted in increased viral replication in association
with a reduced IFN response.
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Methods
Ethics Statement
Ethical approval for this study was obtained from the South-
ampton and South West Hampshire Research Ethics Committees
(A), reference number 05/Q1702/165. Written informed consent
was received from all normal and asthmatic donors who
participated in the study.
Generation and Titration of Human RV1B
RV1B (a gift from Professor Sebastian L. Johnston, Imperial
College, London) was propagated by infecting monolayer cultures
of Ohio HeLa cells (obtained from the American Type Culture
Collection). Viral titers in RV1B stocks and BEC supernatants
were determined by 50% tissue culture infective dose (TCID50)
using Ohio HeLa cells, as described previously [4]. Inactivated
RV1B control was prepared by exposure to UV light at 1200 mJ/
cm2 on ice for 50 min and stored in aliquots at 280uC.
Establishment of Primary Bronchial Epithelial Cells from
Bronchial Brushings and Infection with RV1B
Bronchial brushings were obtained from normal (n = 24) and
asthmatic (n = 35) donors at fibreoptic bronchoscopy following
ethical approval and informed consent. The non-asthmatic
subjects (M:F 9:15, mean age 27.2 (range 20–55)) had a mean
(SD) FEV1 of 103.44 (11.87) % predicted and PC20 methacholine
.16 mg/ml, whilst the asthmatic subjects (M:F 14:21, mean age
40.2 (range 19–70)) had an FEV1 of 85.7 (23.0) % predicted. The
asthmatic donors were either on b2-agonists as sole therapy
(n = 10, geometric mean PC20 2.55 mg/ml, range 0.07–17, or
treated with inhaled steroids, long-acting beta-agonists plus other
therapy [n = 25, no PC20 available]).
Bronchial brushings were cultured until confluent in Bronchial
Epithelial Growth Media (BEGM, Cambrex, Switzerland), as
previously described [4], and were then seeded into 12-well plates
at a cell density 0.46105 cells per well. Once cells reached 90%
confluence, they were placed in BEBM basal medium (Cambrex,
Switzerland), supplemented with 0.1% (w/v) bovine serum
albumin (BSA) and 1% (v/v) insulin/transferrin/sodium selenite
(ITS from Sigma, Poole, UK) for 24 h. Cells were then infected
with RV1B at 1000 or 5000 TCID50 units/10
5 cells for 1 h at
room temperature with shaking. The lower innoculum of virus was
applied to asthmatic PBECs to take into account their increased
susceptibility to RV infection [4]. After infection, cells were
washed and incubated with fresh media for the appropriate times
at 37˚C. Where appropriate, TGF-b2 (Peprotech), an anti-TGF-
b mouse monoclonal antibody (MAB1835, R&D Systems,
Abingdon, UK) that recognizes human TGF-b1 and TGF-b2, or
an IgG isotype control antibody (both at 10 mg/ml) was added
24 h prior to infection and replaced after infection. Synthetic
double stranded RNA (polyinosinic polycytidilic acid, poly IC)
(Autogen Bioclear, Calne, Wiltshire, U.K) was diluted in cell
culture medium before use.
Reverse Transcription and Quantitative Real-time PCR
(RT-qPCR)
Total RNAs were extracted from BECs using TRIzolH reagent
(Invitrogen, Paisley, U.K.), treated to remove contaminating DNA
(DNA-free kit, Ambion, Austin, USA) and cDNA made using
Reverse Transcription Kits (PrimerDesign Ltd, Southampton,
UK). Expression of RV1B vRNA and mRNAs for human IFN-b,
IFN-l/IL-29, TGF-b1, TGF-b2 and TGF-b3 was determined
using real time quantitative PCR and changes in gene expression
expressed relative to the medium control after normalizing to the
geometric mean of the housekeeping genes, ubiquitin C (UBC)
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using
the DDCt method. All PCR reagents were purchased from
PrimerDesign Ltd, Southampton, UK.
Interferon Beta (IFN-b), Interferon l1 (Interleukin-29,IL-
29) and TGF-b ELISAs
IFN-b and IL-29/IFN-l1 release was analyzed using human
IFN-b and IFN-l1/IL-29 ELISA kits (VeriKineTM, NJ, USA)
according to manufacturer’s instructions. Latent and active TGF-
b2 was measured by ELISA (Cat. no. G7600, Promega, South-
ampton, UK). Cross reactivity with 10 ng/ml TGF-b1 was 0.27%
and TGF-b3 0.67%. TGFb1 was measured using an Emax
Immuno Assay System (Cat# G7590, Promega, Southampton,
UK) which shows 1.6% cross-reactivity to 10 ng/ml TGF-b2.
Transformed Mink Lung Cell Bioassay
Active TGF-b was measured using a transformed mink lung
cell/luciferase bioassay as previously described [16].
SDS-PAGE and Western Blotting
PBECs were harvested with lysis buffer and analysed by SDS-
PAGE as previously described [17]. Phospho-SMAD-2 and pan-
SMAD-2 were purchased from Cell Signalling Biotechnology and
used as recommended by the manufacturer.
Statistical Analysis
Where data were normally distributed, they were analyzed
using Student’s paired t test. For non-parametric data, within
group comparisons were performed using Wilcoxon Signed Rank
test and between group comparisons using Mann-Whitney U test.
P,0.05 was considered significant: where statistical significance
was observed, p-values are displayed.
Results
Exogenous TGF- b2 Promotes RV1B Replication and
Reduces Type I and Type III Interferon Expression in
Response to Viral Infection or Double Stranded RNA
Initial dose response experiments examining the effects of TGF-
b2 were performed using PBECs from 3 non-asthmatic volunteers.
Control experiments established that cell viability was high
(.95%) and there were no differences in the levels of cell death
(measured as lactate dehydrogenase release) between TGF-b2
treated and control cells. Following 24 h pre-incubation in serum-
free medium containing 0, 1, 10 or 25 ng/ml TGF-b2, cells were
then infected with RV1B at 5000 TCID50 units/10
5 cells. Analysis
of viral replication at 24 and 48 h post infection revealed a trend
for increased viral RNA at 24 h (Figure 1A) and, by 48 h, there
was an increase in release of infectious viral particles in the
presence of either 10 or 25 ng/ml TGF-b2 (7 and 4-fold increase,
respectively; Figure 1B). This stimulatory effect was confirmed by
testing the effect of TGF-b2 (10 ng/ml) pre-treatment on viral
replication at 48 h using PBECs from a larger number (n = 10) of
non-asthmatic subjects, where a significant increase in viral
replication was observed (Figure 1C). A similar increase in viral
replication was obtained when TGF-b2 was tested using a lower
dose (1000 TCID50 units/10
5 cells) of RV1B (p = 0.012, n = 8)
(data not shown).
We next analyzed the effect of TGF-b on the innate immune
response to RV infection. Measurement of IFN-b protein in
culture supernatants of PBECs from non-asthmatic volunteers
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infected with RV1B for 48 h revealed a significant reduction
(p = 0.027) in IFN-b protein levels from infected cells that were
pre-treated with TGF-b2 compared to those pre-treated in basal
medium alone (Figure 2A). IFN-b protein levels were reduced in
the presence of TGF-b2 in the majority subjects tested. The three
subjects showing the largest suppression of IFN-b showed a 1.8–
Figure 1. The effect of exogenous TGF-b2 on RV replication. PBECs from 3 non-asthmatic volunteers were pre-incubated with 0, 1, 10, and
25 ng/ml of TGF- b2 for 24 h, followed by infection with RV1B at 5000 TCID50 units/10
5 cells. Cells were then further incubated for 48 h in the
presence or absence of TGF-b2, as indicated. Viral replication at 24 h was measured as vRNA by RT-qPCR (A) and at 48 h by release of infectious
virions into culture supernatants by TCID50 assays (B). The graph (C) shows data for infectious virus release from PBECs from 10 non-asthmatic donors
treated without or with 10 ng/ml TGF-b2, followed by infection with RV1B at 5000 TCID50 units/10
5 cells for 48 hours. Statistical comparison was
made using a Wilcoxon rank sum test. The # mark in C indicates where 2 data points overlap (1.8e6R3.1e6 TCID50 units/ml).
doi:10.1371/journal.pone.0044580.g001
Figure 2. Exogenous TGF-b2 suppresses IFN-b release from virally infected (A) or poly IC exposed (B) PBEC cultures from non-
asthmatic donors. PBEC cultures were infected with RV1B (5000 TCID50 units/10
5 cells) (n = 10) or treated with poly IC (n = 5) in the presence or
absence of TGF-b2 which was used at 1 (black bars in B) or 10 ng/ml (panel A and grey bars in B). Culture supernatants were harvested 48 hours p.i (A)
or 8 h post stimulation (B) and IFN-b protein levels were measured by ELISA. In B, the data are expressed as a % of control cultures treated with poly
IC in the absence of TGF-b2 (median (IQR) IFN-b release = 346 (1135) and 369 (1390) pg/ml for cells treated with 1 or 10 mg/ml Poly IC, respectively.
The data were analyzed using Wilcoxon’s rank sum test (A) or using a paired t-test for normally distributed data (B).
doi:10.1371/journal.pone.0044580.g002
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8.1 fold increase in viral replication. In the sole subject that
showed an increase in IFN-b expression following TGF-b treat-
ment, we noted that there was a 19-fold increase in viral
replication compared with a median 4.4 fold increase. As IFN
expression is induced by viral replication, we postulate that in this
case, the unusually high increase in viral load eventually over-rode
the suppressive effect of TGF-b2 to stimulate IFN-b production.
To confirm that the effect of TGF-b2 on IFN-b protein levels
was not simply a consequence of reduced cell number caused by
increased virus-induced cell death, we also measured IFN-b protein
in culture supernatants of PBECs treated for 8 h with poly IC,
a synthetic TLR-3 ligand that mimics the doubled stranded
replicative form of viral RNA and stimulates IFN-b expression
without causing significant cell death. We observed approximately
60% reduction in IFN-b protein levels when cultures were treated
with poly IC (1 mg/ml) together with either 1 or 10 ng/ml
exogenous TGF-b2 compared to cultures treated with poly IC
alone (p = 0.027 and p = 0.026, respectively) (Figure 2B). Using
a higher dose of poly IC (10 mg/ml), we also observed a significant
reduction in IFN-b protein when cells were pre-treated with
10 ng/ml TGF-b2 (p = 0.028) (Figure 2B). In addition to its effects
on Type I IFN production, TGF-b2 also caused a significant
reduction in Type III IFN expression. Thus, IFN-l1/IL-29
protein levels were reduced when PBECs were pre-treated with
TGF-b2 and infected with RV (Figure 3A) or treated with poly IC
(Figure 3B). Of note, the one subject that showed an increase in
IFN-l1/IL-29 release following RV and TGF-b2 treatment was
the same subject that showed an increase in IFN-b production,
Figure 3. Exogenous TGF-b2 suppresses IFN-l1/IL-29 release from virally infected (A) (n=10) or poly IC (n=4) exposed (B) PBEC
cultures from non-asthmatic donors. IFNl1/IL-29 protein levels were measured by ELISA from RV-infected or poly IC exposed PBECs treated with
TGF-b2 as described in Figure 2. Median (IQR) IFN-l1 release = 3896 (2766) and 4932 (4941) pg/ml for cells treated with 1 or 10 mg/ml Poly IC,
respectively.
doi:10.1371/journal.pone.0044580.g003
TGF-Beta Affects Innate Immunity to Rhinovirus
PLOS ONE | www.plosone.org 5 September 2012 | Volume 7 | Issue 9 | e44580
consistent with the unusually high increase in viral replication
observed in this subject.
Neutralizing TGF-b Bioactivity in Asthmatic and Non-
asthmatic PBEC Cultures Resulted in a Greater Reduction
of RV1B Replication in Asthmatic PBEC Compared to
Non-asthmatic PBECs
To determine whether endogenous production of TGF-b might
contribute to the reduced innate immune response of PBECs from
asthmatic donors in response to RV infection [4;5], we compared
the effects of neutralizing antibodies in normal and asthmatic
PBECs infected with RV1B. We observed a significantly greater
decrease in virus replication at 48 h p.i. when PBECs from
asthmatic donors were treated with neutralizing TGF-b antibodies
compared to those from non-asthmatic donors (p = 0.02) (Figure 4).
Further assessment of the effect of TGF-b neutralization using
PBECs from asthmatic donors revealed that at 48 h p.i., the anti-
TGF-b antibody caused a significant reduction in release of
infectious virus particles (Figure 5A). Since production of IFN-b is
dependent on the presence of a ‘danger’ signal (ie. replicating
virus), we analyzed IFN-b protein production as a function of viral
load. This revealed that in the presence of the TGF-b neutralizing
antibody, there was a 3–4 fold increase in IFN-b protein
production when expressed as a function of viral load (Figure 5B).
To confirm the stimulatory effect of anti TGF-b antibodies on
IFN-b production, we also measured IFN-b protein levels
following treatment of PBECs from asthmatic donors with poly
IC. We found a significant increase in IFN-b protein levels
released from cells that were incubated with anti-TGF-b antibody
and 10 mg/ml poly IC, compared to when cells were incubated
with IgG isotype control and poly IC, p = 0.031 (Figure 6A). We
also observed a trend for increased IFNl1/IL-29 protein levels in
the presence of anti-TGF-b antibodies, but this did not reach
statistical significance (Figure 6B).
To determine which isoform of TGF-b was contributing to the
effect of RV, we analyzed mRNA expression of TGF-b1, TGF-b2
and TGF-b3 following RV infection in asthmatic and non-
asthmatic PBECs. Levels of TGF-b3 were substantially lower than
for TGF-b1 and b2, but there was no significant induction of any
TGF-b isoform 24 h after RV infection (Figure 7A); further kinetic
analysis failed to show an earlier or later effect of infection on
TGF-b isoforms expression (data not shown). Even though TGF-
b1 mRNA was detectable, we did not detect TGF-b1 protein by
ELISA in conditioned media from either asthmatic or non-
asthmatic PBECs. In contrast, TGF-b2 protein was not only
detectable but was significantly higher in cultures from asthmatic
donors compared to those in non-asthmatic donors (p = 0.015)
(Figure 7B). However, no active TGF-b2 was detected by ELISA.
Using a transformed mink lung cell bioassay, we were also unable
to detect significant TGF-b activation in the presence of RV
(Figure 7C), and levels of activity were low (average ,25 pg/ml).
Since infection with RV did not affect expression of any TGF-
b isoform, our data suggested that basal endogenous production of
TGF-b contributed to the effect on RV infection. Consistent with
this, SMAD2 phosphorylation was detectable at baseline in non-
infected PBEC cultures and did not increase following RV
infection. However, the endogenous phosphorylation of SMAD2
could be blocked by the TGF-b neutralizing antibody (Figure 8A
and B).
Treatment with Anti TGF-b Antibodies Reduces RV-
mediated Induction of SOCS-1 and SOCS-3
In order to determine the mechanism by which the presence of
endogenous TGF-b suppresses RV1B induced IFN expression, we
measured expression of Suppressors of Cytokine Signalling -1
(SOCS-1) and SOCS-3 that interfere with interferon signaling and
whose expression has been shown to be induced by TGF-b [18].
In our study, we saw an induction of SOCS-1 and SOCS-3
mRNA in the presence of virus alone in PBECs from asthmatic
subjects. When PBECs from asthmatic subjects were treated with
anti-TGF-b antibodies prior to virus infection, both SOCS-1 and
SOCS-3 mRNA were significantly reduced at 48 h p.i., p = 0.031
and p = 0.016 respectively (Figure 9A and 9B).
Discussion
In this study, we have demonstrated that a neutralizing antibody
that blocks endogenous TGF-b activity significantly reduced
RV1B replication in PBECs by increasing IFN expression and
reducing SOCS1 and SOCS3 expression. This protection was
significantly greater in PBEC cultures from asthmatic donors
suggesting that the previously reported susceptibility of asthmatic
PBECs to RV infection [4;5] may be, in part, due to increased
endogenous TGF-b production. We performed our experiments
using monolayer cultures, as these cells have a basal cell phenotype
and can be used to model areas of damaged/repairing epithelium
that are characteristically found in asthmatic airways [10].
Previous studies have shown that basal cells are much more
susceptible to viral infection than fully differentiated epithelial cell
cultures [19], suggesting that these exposed basal cells will be
selectively targeted by RVs that enter the asthmatic lung.
However, endogenous TGF-b expression also appears to be
important factor that influences the susceptibility of differentiated
epithelial cells to RV infection, as we found that neutralization of
endogenous TGF-b also suppressed RV replication in air-liquid
interface cultures (Figure S1). Our finding that PBECs from
asthmatic donors produce more endogenous TGF-b2 than PBECs
from non-asthmatic donors is consistent with findings of higher
levels of TGF-b isoforms in asthmatic mucosa by immunocyto-
chemistry [8;15] and the finding that TGF-b2 is selectively
elevated following allergen challenge [20]. Together, these
findings suggest that the presence of elevated levels of TGF-b2
Figure 4. The effect of neutralizing endogenous TGF-b on RV
replication. PBECs from 8 asthmatic donors or 6 non-asthmatic control
subjects were pretreated for 24 h in the presence of a neutralizing anti
pan TGF-b antibody or isotype control antibody before infection with
RV1B (1000 units/105 cells) for 48 h. The fold-decrease in viral
replication by the neutralizing antibody was plotted as a ratio of the
TCID50/ml of antibody-treated versus isotype controls. The figure shows
median and interquartile range, with individual data points super-
imposed. Data were analysed using a Mann Whitney U test.
doi:10.1371/journal.pone.0044580.g004
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in the bronchial epithelium of asthmatic subjects may contribute to
virus-induced asthma exacerbations. Furthermore, in addition to
endogenously produced epithelial-derived TGF-b2, other sources
of TGF-b isoforms such as eosinophils whose numbers are
increased in asthmatic bronchial epithelium during RV colds
and persist during convalescence [21] may also contribute to
suppression of the innate immune response to RV infection in
asthma.
Analysis of TGF-b isoforms expression revealed that while
TGF-b1 and TGF-b2 mRNAs were readily detectable in PBECs,
TGF-b3 was close to the limit of detection of our RT-qPCR assay.
However, when we examined protein expression, only TGF-b2
was detectable and this was present at significantly higher levels in
Figure 5. Suppression of viral replication in PBECs from asthmatic donors by neutralization of endogenous TGF-b. PBECs from
asthmatic donors were pretreated for 24 h in the presence of a neutralizing anti pan TGF-b antibody or isotype control antibody before infection with
RV1B (1000 units/105 cells) for 48 h. In A, viral titre was determined as TCID50/ml using culture supernatants obtained 48 h p.i. In B, IFN-b protein was
measured at 48 h and was expressed as a ratio of the viral load measured as TCID50 units. The data were analyzed using Wilcoxon’s rank sum test.
doi:10.1371/journal.pone.0044580.g005
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culture supernatants of PBECs from asthmatic donors. Our failure
to detect protein expression of TGF-b1 even though its mRNA was
detectable is consistent with the findings of others [22]. Although
we did not investigate the reason for the higher levels of TGF-b2
expression by PBECs from asthmatic donors, it has been reported
that there are polymorphisms in the TGFB2 gene promoter that
are associated with childhood asthma [23]. In this study, one of the
asthma-associated promoter variants, 2109 RACAA ins, was
a common variant (allele frequency 0.292) and was shown to
increase TGFB2 promoter reporter activity in the BEAS2B
bronchial epithelial cell line. It would therefore be of interest to
investigate the TGFB2 genotype of the donors used in the present
study.
TGF-b isoforms are secreted from cells as latent complexes,
consisting of mature dimeric growth factor, the latency-associated
propeptide (LAP), and latent TGF-b binding protein (LTBP) [24].
Latent TGF-b complexes are normally activated by a diverse
group of mechanisms including proteases, thrombospodin-1 (TSP-
1), integrins such as avb6 and avb6, reactive oxygen species (ROS),
and low pH [25]. While latent TGF-b2 was detectable by ELISA
in culture supernatants, we could not detect active TGF-b2 in
these samples using the same method; we also had limited success
in detection of active TGF-b in a sensitive bioassay using
Figure 6. The effect of anti-TGF-b antibodies on release of IFN-b and IFNl1/IL-29 protein in response to poly IC. PBECs from 6
asthmatic donors were treated with 0.1–10 mg/ml poly IC in the presence of neutralizing anti-TGF-b antibodies (black bars) or an IgG isotype control
(open bars) and incubated for 24 h. Supernatants were removed and IFN-b (A) or IFN-l1/IL-29 protein levels (B) were measured by ELISA. Graphs
show (mean6SEM) IFN produced in pg/ml the presence of the control or anti TGF-b antibodies.
doi:10.1371/journal.pone.0044580.g006
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transformed mink lung cells. However, there was robust TGF-
b activity detected in epithelial cells by phospho-Smad2 immuno-
blots. Based on our observation that exogenous TGF-b2 promoted
viral replication, whereas pan-TGF-b neutralizing antibodies
markedly suppressed viral replication, and the predominance of
TGF-b2 at both message and protein level, our data would suggest
that active TGF-b2 is the predominant isoform promoting viral
replication even though it could not be detected by ELISA. The
failure to release free active TGF-b into cell supernatants is well
described for TGF-b1 that requires direct cell-cell contact for its
activation [26]. Active TGF-b is also known to have a substantially
shorter half-life than the latent form in plasma [27] and several
binding proteins such as a2-macroglobulin allow scavenging of
active TGF-b from the extracellular space to keep the TGF-
b signal local [28]. Furthermore, studies using gene knock out
mice have highlighted the roles of the LTBPs in targeting the
secreted complex to specific locations in the extracellular matrix
[24;25]. This ability to target the latent complex in a specific
manner may explain why our studies with exogenous TGF-b2
required high concentrations of the active TGF-b2 to elicit an
effect, since appropriate targeting of the growth factor was missing.
However, in view of the presence of TGF-b1 mRNA expression in
the PBECs, we cannot exclude the possibility that low levels of cell-
associated active TGF-b1 may have been produced that were not
detectable as free growth factor in the medium. However, the
demonstration of a functional effect of TGF-b2 in the absence of
free active TGF-b2 in cell media raises the intriguing possibility
that TGF-b2 may be activated by an RGD independent change in
its conformational structure.
The pleiotropic effects of TGF-b in vivo and in vitro provides it
with various roles in growth and development, inflammation and
repair and host immunity [29;30]. One effect of TGF-b is to cause
cell cycle arrest and induction of apoptosis in vitro through complex
signalling pathways involving SMAD proteins [29]. In epithelial
cells, TGF-b has been shown to cause G1 cell cycle arrest by
activation of anti-proliferative responses such as the transcriptional
up-regulation of the cyclin-dependent kinase inhibitors p21Cip1/
WAF1 and p15 Ink4b [31;32]. Since apoptosis is a key mechanism
that limits viral replication [33], it might have been expected that
endogenous TGF-b would dampen RV1B replication. However,
Figure 7. The effect of RV infection on TGF-b isoform expression. TGF-b1, b2, b3 mRNA levels were measured in PBECs from 4 asthmatic and
4 non-asthmatic donors following infection with RV; TGF-bmRNA expression was measured relative to GAPDH/UBC using the DDCt method (A). Total
TGF-b2 protein levels were measured in conditioned media from PBEC cultures of 15 non-asthmatic and 23 asthmatic donors which were harvested at
48 h. Latent TGF-b2 was activated by acid-treatment and total TGF-b2 measured by ELISA. Statistical significance was tested using Mann Whitney U
test (B). PBEC culture supernatants of 2 non-asthmatic and 4 asthmatic donors were tested in a transformed mink lung cell luciferase bioassay in order
to measure active TGF-b in the presence (black bars) or absence (grey bars) of rhinovirus at 5000 TCID50 units/10
5 cells. Superimposed is a standard
curve obtained using 250 or 500 pg of active TGFb (C). Data in panels A and B are given as box and whisker plots showing median, interquartile range
and 95% confidence intervals; individual data points are superimposed.
doi:10.1371/journal.pone.0044580.g007
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we could find no effect of anti TGF-b antibodies on caspase
activation (Figure S2) and RV1B replication was consistently
decreased in the presence of anti TGF-b antibodies. These
findings contrast with studies of RSV infection which have
reported that exogenous TGF-b1 is beneficial for RSV replication
[12] via mechanisms that involved cell cycle arrest [34]. Of
interest, RSV infection also augmented TGF-b production by
infected epithelial cells, although in our own studies, we could find
no evidence of increased TGF-b isoform mRNA expression
following RV infection. Instead, our data suggested that rather
than containing virus infection by inducing apoptosis, the presence
of high endogenous level of this cytokine promoted virus
replication by suppressing the innate immune response.
In addition to its role in regulating the cell cycle, TGF-b also
plays a role in the control of innate and adaptive immunity. Thus,
TGF-b plays a role in promotion of Th17 lineage commitment
and has been implicated in the initial amplification of the innate
immune response through recruitment of monocytes and neu-
trophils [35], [36]. It also has important anti-inflammatory roles
including coordination of regulatory T cell (Treg) development
and function including suppression of Th1 and Th2 cell de-
velopment [30]. While the responses to TGF-b are closely
regulated by environmental stimuli and the accompanying
cytokine milieu, the extremely pleiotropic nature of this cytokine
has led to the suggestion that TGF- b can ‘‘act as a light switch: i.e.
if it’s on, it will turn it off; if it’s off, it will turn it on [34].’’ In our
experiments, we observed that endogenous TGF-b acts more like
an anti-inflammatory cytokine as treatment with neutralizing
antibodies promoted induction of both type I and type III
interferon responses to either virus infection or the synthetic
dsRNA, poly IC. This observation is the first report that TGF-
b can directly affect expression of Type III interferon and extends
previous studies in bronchial fibroblasts where the authors found
a dampening of IFN-b expression following rhinovirus infection in
the presence of TGF-b1 [14]. However, in the latter case, the
authors reported that the effect of TGF-b1 appeared to be rapid
and mediated via effects on IFN regulatory factor (IRF)-3
pathways [14]. In contrast, in our studies with PBECs, the effect
of TGF-b was slow and appeared to involve members of the
SOCS family of suppressors of cytokine signaling as evidenced by
decreased SOCS-1 and SOCS-3 gene expression when we blocked
endogenous TGF-b. SOCS-1 and SOCS-3 do not interfere with
direct TLR signaling, but avoid overshooting activation by
regulating IFN-b signaling [37] and both have been shown to be
Figure 8. The effect of TGF-b neutralization on basal SMAD2 activation. PBECs from asthmatic donors were treated with RV and anti TGF-
b antibody, as indicated, as described in Figure 5. Cell lysates were harvested at 1, 4, and 6 hours post-virus infection and Smad-2 phosphorylation
was analysed by Western blotting. A representative Western blot is shown in (A) and densitometric quantification of the experiment repeated using
PBECs from 3 different asthmatic subjects is shown in (B).
doi:10.1371/journal.pone.0044580.g008
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induced by TGF-b [18]. Using siRNA targeting SOCS-3, we were
able to significantly knockdown SOCS-3 expression and found
a trend for increased IFN-b release when epithelial cells were
treated with poly IC in the presence of TGF-b (Figure S3).
However, as we were unable to significantly knock down SOCS-1
using the same approach, we were unable to test the cumulative
effect of attenuating the inhibitory effects of both suppressor
proteins. Thus, while further work is still required to demonstrate
causality between SOCS-1 and -3 and modulation of the IFN
response, the slow kinetics of the anti TGF-b effect on viral
replication are more consistent with a slow, cumulative effect of
TGF-b involving increased SOCS expression and suppression of
IFN-b signalling rather than blockade of the initiating signal
involving IRF-3. Of further note is the occurrence of genetic
polymorphism in the SOCS-1 gene where a particularly significant
association has been found between asthma susceptibility and
a promotor polymorphism (-1478CA) which was shown to cause
increased transcription of SOCS-1 [38]. Thus, there is a potential
Figure 9. Neutralizing endogenous TGF-b suppresses RV1B mediated SOCS-1 and SOCS-3 gene expression in asthmatic PBECs.
Samples were treated as described in Figure 5. SOCS-1 (A) and SOCS-3 (B) gene expression were measured in 7 asthmatic subjects at 48 h p.i. by RT-
qPCR and normalized to housekeeping genes. Results were plotted as relative fold-induction using the DDCt method. The Wilcoxon rank sum test
was used to analyse statistical significance.
doi:10.1371/journal.pone.0044580.g009
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for gene-gene interactions involving polymorphisms in the TGFB2
and SOCS1 genes linked to virus-induced asthma exacerbations.
In conclusion, our data suggest that higher levels of endogenous
TGF-b expression contribute to the decreased innate immune
response to virus infection in asthmatic epithelial cells. This
involved reduction of both IFN-b and IFNl1/IL-29 mRNA and
protein expression in response to RV infection and was mirrored
by similar responses when the cells were exposed to the TLR3
agonist, poly IC. This response was associated with higher
endogenous levels of TGF-b2 protein and elevated SOCS1 and
SOCS3 expression that could be down-regulated by TGF-
b neutralizing antibodies. Although not investigated directly, our
data suggest that genetic polymorphisms in either the TGFB2 or
SOCS-1 gene may dictate varying degrees of susceptibility to virus
infection in asthma. There is also the possibility that production of
other isoforms of TGF-b by cell types such as eosinophils, whose
numbers are increased in asthmatic bronchial epithelium during
rhinovirus colds and persist during convalescence [21], may also
directly contribute to virus-induced exacerbations by affecting the
ability of epithelial cells to mount an adequate innate anti-viral
immune response.
Supporting Information
Figure S1 The effect of neutralizing anti-TGF-b antibodies on
rhinovirus replication in PBECs grown on air-liquid interface
(ALI). PBECs from 5 subjects were differentiated at an air-liquid
interface for 3 weeks, as previously described (Xiao et al. J Allergy
Clin Immunol 128, 549–556, 2011). Cells were then pre-treated
apically and basolaterally for 24 h with anti-TGF-b or an isotype
control (10 mg/ml), followed by RV1B infection (MOI = 5) for 6 h.
The virus was then washed off and cells were further incubated for
18 or 42 h in the presence of anti-TGF-b (aTGFb) or an isotype
(IgG1) control. Apical washes were analysed for the release of viral
particles as TCID50/ml after 24 h (A) (n = 5) or 48 h (B) (n = 4)
from the start of infection.
(DOCX)
Figure S2 Caspase 3/7 activity of RV1B-infected PBEC in the
presence or absence of TGF-b. PBECs from a healthy donor were
seeded into a collagen-coated 96-well plate and incubated
overnight at 37uC. Cells were then pre-treated with TGF-b2
(10 ng/ml) and incubated for 24 hrs after which they were
infected with RV1B (MOI = 0.05) for 1 hour, washed, and further
incubated in media for 4, 8, and 24 hrs in the absence or presence
of TGF-b2. After each time point, a luminogenic caspase-3/7
substrate was added to each sample and incubated for 1 hour.
Luminescence was measured on a TopCount plate reader.
(DOCX)
Figure S3 The effect of SOCS-3 knockdown on IFN-b protein
in TGF-b treated PBECs. PBECs were transfected with 100 nM
siRNA targeted against SOCS-3 (SOCS-3) or a negative control
siRNA (Neg) for 24 h followed by treatment with 1 mg/ml poly IC
for 8 hours in the presence or absence of 10 ng/ml TGF-b2. A:
Cell conditioned media were analysed for secreted IFN-b protein;
the data are expressed as a percent of cells treated with the
Negative control siRNA and poly IC in the absence of TGF-
b (n = 4). B: SOCS-3 mRNA expression was determined by RT-
qPCR. There was significant suppression of SOCS-3 expression in
the presence of SOCS-3 siRNA compared with control (P,0.02)
(DOC)
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